Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Gross Profit: 2018-2025

Historic Gross Profit for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to $11.7 million.

  • Bicycle Therapeutics' Gross Profit rose 338.49% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.7 million, marking a year-over-year decrease of 194.16%. This contributed to the annual value of $1.2 million for FY2024, which is 77.36% down from last year.
  • As of Q3 2025, Bicycle Therapeutics' Gross Profit stood at $11.7 million, which was up 301.85% from $2.9 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Gross Profit registered a high of $11.7 million during Q3 2025, and its lowest value of -$30.4 million during Q4 2024.
  • In the last 3 years, Bicycle Therapeutics' Gross Profit had a median value of $5.4 million in 2023 and averaged $2.0 million.
  • Per our database at Business Quant, Bicycle Therapeutics' Gross Profit spiked by 950.00% in 2022 and then crashed by 294.58% in 2023.
  • Quarterly analysis of 5 years shows Bicycle Therapeutics' Gross Profit stood at $800,000 in 2021, then skyrocketed by 950.00% to $8.4 million in 2022, then slumped by 294.58% to -$16.3 million in 2023, then slumped by 85.79% to -$30.4 million in 2024, then soared by 338.49% to $11.7 million in 2025.
  • Its Gross Profit stands at $11.7 million for Q3 2025, versus $2.9 million for Q2 2025 and $10.0 million for Q1 2025.